A Rare Complication Related with Oral Anticoagulant (Warfarin) Use: Diffuse Alveolar Hemorrhage (above 65 Years 4 Case Reports)

Serap Duru*, Bahar Kurt, Merve Yumrukuz and Esra Erdemir

Dışkapı Yıldırım Beyazıt Training and Research Hospital, Chest Diseases Clinic, Ankara, Turkey

Abstract

Diffuse alveolar hemorrhage (DAH) caused by immune and non-immune etiological factors, characterized by diffuse alveolar consolidation often presents with the clinical triad of dyspnea, hemoptysis, anemia, as a result of the disruption of the alveolocapillary membrane of the lung. We aimed to present above 65 years 4 cases followed in our clinic with diffuse alveolar hemorrhage as a rare complication of uncontrolled use of anticoagulant (warfarin) therapy. The cases was diagnosed as diffuse alveolar hemorrhage based on clinical, radiological and bronchoscopic data. After warfarin treatment was withdrawn, clinical and radiological signs recovered rapidly and the existent situation was thought to be DAH related with warfarin use after excluding other reasons. We think that the current cases is a rare disease of warfarin therapy leading to DAH.

Introduction

According to World Health Organization data, elderly population in the world, which constantly increases, is expected to reach 1.2 billion by 2025 [1]. Due to chronic diseases occurring in this age group, the amount of drug used increases, hence they should be regularly monitored. Diffuse alveolar hemorrhage, is a disorder developing due to immune and non immune etiological factors and characterized by shortness of breath, hemoptysis, anemia, and diffuse alveolar consolidation as a consequence of alveolocapillary membrane damage in lungs. Its most common causes are collagen tissue diseases, infectious or toxic exposures, neoplastic diseases, and pulmonary thromboembolism [2]. In the elderly population, oral anticoagulants are the most commonly used drugs in order to prevent thromboembolic complications. During treatment with oral anticoagulants, various bleeding complications may occur during treatment with oral anticoagulants but the development of DAH is quite rare [3,4]. The aim of the present report was to present four cases over the age of 65 who presented to emergency service consecutively due to DAH, which is a rare complication among warfarin associated hemorrhage.

Case Report

It was learned that 4 cases (2 females) over the age of 65 presenting to emergency service with the complaints of shortness of breath, cough and hemoptysis have used warfarin at an uncontrolled dose for the last three years. One used it for previous coronary bypass and atrial fibrillation while the other three for heart valve replacement. In physical examination, end inspiratory rales were present especially in bilateral infrascapular regions. In all of the four cases, decrease of respiratory rate (≤20/min) and body temperature 37 degree. In the examination of upper respiratory tract, no malignant cells were observed. Following supportive treatment including oxygen administration, vitamin K replacement, one case had right atrial enlargement and minimal deficiency in tricuspid valve.

In hemorragic lavage fluid obtained, hemosiderin laden macrophages were observed in addition to erythrocytes. In lavage fluid, ARB was negative and there was no growth in culture. In cytological examination, no malignant cells were observed. Following supportive treatment including oxygen administration, vitamin K replacement, respiratory failure and compliance problems could not undergo carbonmonoxide diffusion test (DLCO). In two cases, increase in DLCO was established. Investigations for carried out differential diagnosis of DAH. That is, cytoplasmic and perinuclear cytoplasmic antibody, antishlomerular basement membrane antibodies, antinuclear antibody, anti-ds DNA antibodies, complement level, rheumatoid factor, TORCH panel, serum D-dimer level, urinalysis and genetic examinations were found to be normal. When the history of being exposed to a toxic agent via inhalation, drugs used and smoking and drug habits were questioned, It was learned that two male patients had a smoking history of 15-20 pack-year, but did not have any clinical symptom of chronic airway disease. In order to rule out lung infections that can lead to the same clinical picture, in sputum ARB. And gram positive staining was made with detection of no pathogens. In echocardiographic examination, it was established that left ventricle functions were adequate (EF 60%) an done case had right atrial enlargement and minimal deficiency in tricuspid valve.

Diffuse alveolar hemorrhage (DAH) caused by immune and non-immune etiological factors, characterized by diffuse alveolar consolidation often presents with the clinical triad of dyspnea, hemoptysis, anemia, as a result of the disruption of the alveolocapillary membrane of the lung. We aimed to present above 65 years 4 cases followed in our clinic with diffuse alveolar hemorrhage as a rare complication of uncontrolled use of anticoagulant (warfarin) therapy. The cases was diagnosed as diffuse alveolar hemorrhage based on clinical, radiological and bronchoscopic data. After warfarin treatment was withdrawn, clinical and radiological signs recovered rapidly and the existent situation was thought to be DAH related with warfarin use after excluding other reasons. We think that the current cases is a rare disease of warfarin therapy leading to DAH.

*Corresponding author: Serap Duru, Dışkapı Yıldırım Beyazıt Research and Education Hospital, Ankara, Turkey, Tel: +90 505 3124191; E-mail: akcalis@hotmail.com

Received October 21, 2014; Accepted July 02, 2015; Published July 07, 2015


Copyright: © 2015 Duru S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
And erthrocyte suspension and discontinuation of warfarin, clinical and radiological findings rapidly improved and our cases were discharged uneventfully.

**Discussion**

Diffuse alveolar hemorrhage complicating warfarin therapy may be a high mortality rate. Diffuse alveolar hemorrhage, which does not have a specific laboratory and clinic diagnosis method, leads to a clinical picture ranging from cough, hemoptysis, shortness of breath to respiratory failure particularly in elderly patients. When this clinical picture is observed in patients on warfarin and infiltrations are detected in direct lung graphy. Diffuse alveolar hemorrhage should be among infiltrative lung diseases that should be kept in mind in differential diagnosis [5]. Of our cases, consistent with this clinical spectrum, cough, hemoptysis and breathlessness was found in three, while in one additionally respiratory failure was seen.

In DAH, definitive diagnosis is made by lung tissue biopsy guided by fiberoptic bronchoscopy. Bronchoscopic biopsy may have risk of fatality due to excessive mucosal hemorrhagia and severe respiratory failure [6]. Our purpose of bronchoscopy is primarily to see the intra-alveolar blood, exclude endobronchial lesion and infection. In this case, the detection of hemosiderin laden alveolar macrophages in BAL with hemorrhagic appearance supports the diagnosis. Actually, the appearance of hemosiderin laden alveolar macrophages in our cases in BAL suggested the diagnosis of DAH.

There are many reason in DAH etiology. Among collagen tissue diseases, Wegener granulomatosis [7,8], systemic lupus erythematosus [9,10] and Goodpasture syndrome [11], give rise to DAH owing to immun deposits in alveoler intertsium and intra-alveolar blood vessels. In addition, drugs such as cocain, difenylhidantoin and leflunomid may lead to DAH [12]. We investigated other etiologic factors and serum levels of collagen tissue marker (C-ANCA, P-ANCA, ANA and anti ds-DNA) were analyzed. We did not find any problem for DAH in our cases. It is determined that the clinical picture in our cases is that of DAH which occurs rarely without any systematic involvement other than pulmonary involvement.

Warfarin is a commonly prescribed anticoagulant all over the world. Diffuse alveolar hemorrhage associated with warfarin was first described by Brown et al. [13]. Subsequently, limited number of cases have been presented [4,14]. Therefore, we believed that our series of four cases may contribute the literature regarding this subject. In a previous study, it was reported that of all cases followed in hospital with side effects of drugs, 10% was associated with DAH owing to warfarin. Care should be exercised in the follow up patients on warfarin and it should be borne in mind that, it may lead to DAH, albeit rarely, which has high mortality unless diagnosed and treated early.

**Conclusion**

Diffuse alveolar hemorrhage is a life threatening complication which may develop due to many etiologic factors. World population is getting older and the elderly living alone is increasing in all over the world. So it is difficult to track medication use in the elderly. In warfarin associated DAH cases, especially elderly cases who regularly used the drug should be warned against the risk of hemorrhage and should be regularly monitorized by clinicians. Early diagnosis is very important in DAH. The diagnosis must be clinically and radiologically and bronchoscopy.

**References**


